Technical Analysis for TLC - Taiwan Liposome Company, Ltd.

Grade Last Price % Change Price Change
grade F 5.15 -4.59% -0.25
TLC closed down 4.59 percent on Tuesday, February 18, 2020, on 1.11 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical TLC trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Crossed Above 200 DMA Bullish -4.59%
Crossed Above 20 DMA Bullish -4.59%
Crossed Above 50 DMA Bullish -4.59%
Narrow Range Bar Range Contraction -4.59%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Taiwan Liposome Company, Ltd., a biopharmaceutical company, engages in the research, development, and commercialization of lipid-based pharmaceutical products. The company offers products in the areas of oncology, ophthalmology, peripheral arterial disease, fungal infection, anesthetic, and arthritis indications. Its products include Lipotecan, an anti-cancer camptothecin drug; Doxisome, a liposomal encapsulated formulation of doxorubicin; TLC178, a liposomal encapsulated formulation of vinorelbine; ProDex, an ophthalmic drug for the treatment of macular edema; ProFlow, an emulsion form of prostaglandin E1; AmBiL, a liposomal encapsulated formulation of amphotericin B; TLC198, a liposomal encapsulated bupivacaine, enabling the sustained release of a constant amount of local anesthetic; and TLC599, a corticosteroid encapsulated in lipid based drug delivery system for the treatment of inflammation caused by arthritis. The company was founded in 1997 and is headquartered in Taipei City, Taiwan.
Biopharmaceutical Drugs Inflammation Pharmacology Drug Delivery Arthritis Macular Edema Peripheral Arterial Disease Amphotericin B Arbutus Biopharma Bupivacaine Doxorubicin Liposome

Is TLC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.0
52 Week Low 4.61
Average Volume 3,860
200-Day Moving Average 5.36
50-Day Moving Average 5.32
20-Day Moving Average 5.34
10-Day Moving Average 5.23
Average True Range 0.30
ADX 36.63
+DI 45.53
-DI 17.45
Chandelier Exit (Long, 3 ATRs ) 4.94
Chandelier Exit (Short, 3 ATRs ) 5.74
Upper Bollinger Band 5.75
Lower Bollinger Band 4.94
Percent B (%b) 0.26
BandWidth 15.12
MACD Line -0.04
MACD Signal Line -0.02
MACD Histogram -0.0124
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.80
Resistance 3 (R3) 5.87 5.72 5.69
Resistance 2 (R2) 5.72 5.56 5.69 5.65
Resistance 1 (R1) 5.44 5.46 5.37 5.37 5.62
Pivot Point 5.29 5.29 5.26 5.26 5.29
Support 1 (S1) 5.01 5.13 4.94 4.94 4.68
Support 2 (S2) 4.86 5.03 4.83 4.65
Support 3 (S3) 4.58 4.86 4.61
Support 4 (S4) 4.51